We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Gilead Developing Sovaldi Partnerships, Access Programs for Indian Market
Gilead Developing Sovaldi Partnerships, Access Programs for Indian Market
Gilead is yielding to pressure to reduce the price of its game-changing hepatitis C drug Sovaldi just weeks after it hit the U.S. market, developing an access program as well as licensing partnerships with generic drugmakers in India to manufacture cheaper versions of the drug for the Indian market.